The encoded EPHA3 protein is a receptor tyrosine kinase that promiscuously binds membrane-bound ligands of the ephrin family located on neighboring cells, resulting in contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling, while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling.
The receptor is highly promiscuous for ephrin A ligands and preferentially binds EFNA5. Upon activation by EFNA5, it regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in the migration and differentiation of cardiac cells and regulates the formation of the atrioventricular canal and septum during development, probably through activation by EFNA1. Is involved in retinotectal mapping of neurons. May also control segregation, but not guidance, of motor and sensory axons during development of the neuromuscular circuit.
Eph receptors are the largest family of receptor tyrosine kinases (RTKs) and are divided into two subclasses, EphA and EphB. Eph receptors were originally identified as mediators of axon guidance and are involved in many processes, particularly cancer development and progression.
Eph receptors were originally identified as mediators of axon guidance. They are involved in many processes, including vascular development and carcinogenesis and progression.
The following causes of abnormal and dilated blood vessels can be summarized for the nevus flammeus (Liu L et al. 2022):
- Somatic GNAQ (R183Q) mutations that induce angiopoietin-2 lead to the formation of enlarged capillary-like vessels
- Decreased number of perivascular nerve elements
- Coexistence of Eph receptor B1 and ephrin B2
- Lack of expression of alpha-smooth muscle actin
- Mutations in the PIK3CA, SMARCA4, EPHA3, MYB and PDGFR-B genes
Eph receptor tyrosine kinases regulate cell-cell interactions during normal and oncogenic development and are involved in a number of processes, including angiogenesis, stem cell maintenance and metastasis. They are therefore of great interest as targets for cancer therapy. EphA3, which was originally isolated from leukemia and melanoma cells, is currently one of the most promising therapeutic targets as it plays a tumor-promoting role in a variety of cancers (Janes PW et al. 2014).
In melanoma , the EPH receptor A3 (EphA3) is deregulated . Its role has not yet been clarified in detail (Ming D et al. 2022).